Solid Malignancies
Conditions
Brief summary
This is a first-in-human (FIH), phase 1, multicenter, open-label study of SKB571 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity in adult subjects with advanced or metastatic solid tumor .
Detailed description
This is a first-in-human (FIH), phase 1, multicenter, open-label study of SKB571 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity in adult subjects with advanced or metastatic solid tumor.
Interventions
DRUGSKB571
SKB571 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
Sponsors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects aged 18-75 years at the time of signing the informed consent form 2. Subjects with histologically or cytologically confirmed locally advanced or metastatic solid tumors . 3. Subjects with at least one measurable lesion assessed by the investigator according to RECIST v1.1. 4. Subjects with Eastern Cooperative Oncology Group (ECOG) status score of 0 or 1. 5. Subjects who are assessed by the investigator to have an expected survival of ≥ 3 months. 6. Subjects who have adequate organ function. 7. Subjects who have recovered from all toxicities due to prior therapy . 8. Male and female subjects must agree to use highly effective contraception methods during the study treatment. 9. Subjects who voluntarily sign the informed consent form.
Exclusion criteria
1. Subjects with known active or untreated central nervous system (CNS) metastases. 2. Subjects with other malignant tumors within 3 years prior to the first dose. 3. Subjects with history of major cardiovascular, cerebrovascular, or thromboembolic disease. 4. Subjects with known active pulmonary tuberculosis. 5. Subjects with human immunodeficiency virus (HIV) infection, or any known active viral hepatitis, or hepatitis B or hepatitis C. 6. Subjects with major surgery within 28 days prior to the first dose. 7. Subjects with known allergy or hypersensitivity to SKB571 or its excipients. 8. Subjects with clinically severe lung injuries due to pulmonary complications. 9. Subjects with a history of allogeneic tissue/solid organ transplant. 10. Uncontrolled pleural effusion, pericardial effusion, or ascites effusion requiring repeated drainage. 11. Subjects who have received live vaccines within 30 days prior to the first dose of study treatment, or who are scheduled to receive live vaccines during the study. 12. Subjects who have received strong cytochrome P450 (CYP3A4) inhibitors or inducers, or BCRP inhibitors within 2 weeks prior to the first dose of study treatment or within 5 half-lives of known drug, whichever is longer. 13. Subjects who have received chemotherapy, immunotherapy, or biological therapy within 4 weeks prior to the first dose of study treatment. 14. Subjects with active infection requiring systemic anti-infective therapy within 14 days prior to the first dose of study treatment. 15. Subjects with any disease requiring systemic treatment with corticosteroids (prednisone at doses \> 10 mg/d or similar drugs with equivalent doses) or other immunosuppressive therapy within 14 days prior to the first dose of study treatment. 16. Subjects have received an investigational agent or has used an investigational device within 28 days prior to initial dose administration of SKB571. 17. Subjects whose condition deteriorates rapidly before the first dose, such as a severe physical impariment or a change in ECOG score no longer meeting the inclusion criteria. 18. Subjects with a known history of psychosis or drug abuse that will preclude the subject from completing the study. 19. Any condition that, in the opinion of the investigator, will interfere with the assessment of study treatment or the safety of the subject or the interpretation of the study results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects achieving Dose-limiting toxicity (DLT) | From data of initial dose until up to 21 days for treatment | DLT is defined as an adverse event (AE) that meets protocol defined DLT criteria during cycle 1 and is at least possibly related to study drug. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Up to 24 months | The sum of the number of cases with Complete Response (CR) and Partial Response (PR) in all treated tumor patients (CR + PR) divided by the total number of cases. |
| Progression Free Survival (PFS) | Up to 24 months | Time from start of treatment to progression of disease (PD) or death, whichever occurs first, in patients with tumors. |
| Duration of Response (DOR) | Up to 24 months | Time from the start of the first assessment of CR or PR in tumor patients to PD or death due to any reason. |
| Overall Survival (OS) | Up to 24 months | Time from start of treatment to death due to any reason. |
Countries
China
Contacts
CONTACTXin Li
Outcome results
None listed